MW 151.16 Da, Purity >98%. Selective COX-3 inhibitor (IC50 = 460 μM). NSAID with widely used analgesic and antipyretic effects. Blood-brain barrier permeable.
5-lipoxygenase activating protein, AHH, AL5AP_HUMAN, ALOX 5AP, Arachidonate 5-lipoxygenase-activating protein, Aryl hydrocarbon hydroxylase, CA 1, CA 12, CA 13, CA 14, CA 2, CA 7, CA IV, CA-I, CA-II, CA-III, CA-VII, CA-XII, CA-XIII, CA-XIV, CA13 carbonic anhydrase XIII, CA4, CAB, CAC, CAH12_HUMAN, CAH13_HUMAN, CAH14_HUMAN, CAH1_HUMAN, CAH2_HUMAN, CAH4_HUMAN, CAH7_HUMAN, CP11, CP1A1_HUMAN, CYP 1, CYPIA1, Car 1, Car 2, Car3, Car4, Carbonate dehydratase I, Carbonate dehydratase II, Carbonate dehydratase III, Carbonate dehydratase IV, Carbonate dehydratase VII, Carbonate dehydratase XII, Carbonate dehydratase XIII, Carbonate dehydratase XIV, Carbonic anhydrase 1, Carbonic anhydrase 12, Carbonic anhydrase 13, Carbonic anhydrase 14, Carbonic anhydrase 2, Carbonic anhydrase 3, Carbonic anhydrase 4, Carbonic anhydrase 7, Carbonic anhydrase A, Carbonic anhydrase B, Carbonic anhydrase B, formerly, Carbonic anhydrase C, Carbonic anhydrase C, formerly, Carbonic anhydrase I, Carbonic anhydrase II, Carbonic anhydrase III muscle specific, Carbonic anhydrase VII, Carbonic anhydrase XII, Carbonic anhydrase XIII, Carbonic anhydrase XIV, Carbonic dehydratase, Carbonic dehydratase IV, Carbonic dehydratase VII, Cyclooxygenase, Cyclooxygenase 2b, Cyclooxygenase-2, Cytochrome P1 450 dioxin inducible, Cytochrome P1-450, Cytochrome P450 1A1, Cytochrome P450 family 1 subfamily A polypeptide 1, Cytochrome P450 form 6, Cytochrome P450 subfamily I (aromatic compound inducible) polypeptide 1, Cytochrome P450-C, Cytochrome P450-P1, EC 1.14.99.1, EC 4.2.1.1, EC=4.2.1.1, ECK0125, Epididymis secretory protein Li 282, FLJ00280, FLJ00318, FLJ16020, FLJ16733, FLJ20151, Five lipoxygenase activating protein, GRIPGHS, Glucocorticoid-regulated inflammatory Prostaglandin G/H synthase, Glucocorticoid-regulated inflammatory cyclooxygenase, HEL-76, HEL-S-282, HsT18816, JW0122, MB, MGC102720, MGC13548, MK-886-binding protein, MYG_HUMAN, Macrophage activation-associated marker protein P71/73, Microsomal monooxygenase, Myoglobin, NR1B1, NR2B1, Nuclear mitotic apparatus protein retinoic acid receptor alpha fusion protein, Nuclear receptor subfamily 1 group B member 1, Nuclear receptor subfamily 2 group B member 1, Nucleophosmin retinoic acid receptor alpha fusion protein NPM RAR long form, OTTHUMP00000022510, OTTHUMP00000033524, P1 450, P450 C, P450 P1, P450 form 6, P450DX, PES-2, PGG/HS, PGH synthase 2, PGH2_HUMAN, PGHS-2, PHS 2, PHS II, PTGS2, Prostaglandin G/H synthase, Prostaglandin G/H synthase 2, Prostaglandin G/H synthase 2 precursor, Prostaglandin G/H synthase and cyclooxygenase, Prostaglandin H2 synthase 2, Prostaglandin-endoperoxide synthase 2, RAR, RAR-alpha, RARA_HUMAN, RARalpha1, RP17, RXR alpha1, RXRA_HUMAN, Retinitis pigmentosa 17 (autosomal dominant), Retinoic acid nuclear receptor alpha variant 1, Retinoic acid nuclear receptor alpha variant 2, Retinoic acid receptor RXR-alpha, Retinoic acid receptor alpha, Retinoic acid receptor alpha polypeptide, Retinoid X nuclear receptor alpha, Retinoid X receptor alpha, T18816, TIS10, TIS10 protein, Tumor antigen HOM-RCC-3.1.3, UNQ690/PRO1335, Xenobiotic monooxygenase, epididymis luminal protein 76, fj02a10, flavoprotein-linked monooxygenase, hCox 2, prostaglandin-endoperoxide synthase 2 (prostaglandin G/H synthase and cyclooxygenase), ptgs2a, unp1239, wu:fj02a10, yadF
MW 151.16 Da, Purity >98%. Selective COX-3 inhibitor (IC50 = 460 μM). NSAID with widely used analgesic and antipyretic effects. Blood-brain barrier permeable.
Soluble in water to 100 mM.
Soluble in DMSO to 100 mM.
Soluble in ethanol to 100 mM.
Selective COX-3 inhibitor (IC50 = 460 μM). NSAID with widely used analgesic and antipyretic effects. Blood-brain barrier permeable.
Myoglobin is a well-known protein involved in oxygen binding within muscle tissues. It carries a molecular mass of approximately 16.7 kDa. Expressed mostly in cardiac and skeletal muscle it functions similarly to hemoglobin but operates within muscle cells. Another important protein Carbonic Anhydrase 2 (CA2) aids in the reversible hydration of carbon dioxide and is chiefly found in erythrocytes and renal tubules with a mass around 29 kDa. COX2 or Cyclooxygenase 2 plays a role in inflammation and pain through prostaglandin production and is expressed in various tissues under inflammatory conditions. Retinoic Acid Receptor alpha (RARα) and Retinoid X Receptor alpha (RXRA) are nuclear receptors engaged in gene regulation processes. FLAP is essential in leukotriene biosynthesis—an important component of inflammation.
These proteins participate in significant physiological and cellular roles. Myoglobin for example stores oxygen in muscle cells enabling efficient muscle contraction. CA2 along with its isozymes like CA1 (expressed in RBCs) CA4 (on endothelial cells) and others regulates acid-base balance and fluid movement. COX2 acts in synthesizing signaling molecules involved in inflammation. RARα and RXRA often partnering in complexes control gene expression by regulating retinoic acid-responsive genes. FLAP's involvement in leukotriene synthesis connects it with immune responses and inflammation.
These proteins integrate into critical biological processes. Myoglobin and CA2 along with CA1 and CA12 align in oxygen transport and carbon dioxide management within the respiratory and bicarbonate buffer systems. COX2 is involved in the arachidonic acid pathway closely aligned with inflammation and bleeding processes interacting with proteins such as prostaglandin E synthase. RARα and RXRA partake in the retinoic acid signaling pathway influencing numerous genes associated with differentiation and metabolism.
Altered levels or activities of these proteins relate to conditions like cardiovascular disease and cancer. CA2 and its related isoforms such as CA4 and CA7 show linkage to disorders including glaucoma and renal tubular acidosis. COX2 by fueling inflammation is connected to chronic inflammatory diseases like arthritis and certain cancers often alongside prostaglandins as mediators. RARα dysregulation is notably involved in acute promyelocytic leukemia while myoglobin release from damaged muscle can lead to myoglobinuria signaling muscle injury.
We are dedicated to supporting your work with high quality reagents and we are here for you every step of the way should you need us.
In the unlikely event of one of our products not working as expected, you are covered by our product promise.
Full details and terms and conditions can be found here:
Terms & Conditions.
2D chemical structure image of ab120990, Acetaminophen, COX-3 inhibitor
Please note: All products are 'FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC OR THERAPEUTIC PROCEDURES'.
For licensing inquiries, please contact partnerships@abcam.com